Specific potassium channel blockade for arrhythmia prevention in the ionically remodeled failing heart: peril or panacea?
Nattel
Stanley
S
Department of Medicine and Research Center, Montreal Heart Institute, University of Montreal, Montreal, Quebec H1T 1C8, Canada. Stanley.nattel@icm-mhi.org
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control*; D002839:Chromans / Q000627:therapeutic use*; D004285:Dogs; D006333:Heart Failure / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; D026902:Potassium Channel Blockers / Q000627:therapeutic use*; D024681:Potassium Channels, Calcium-Activated / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000627:therapeutic use*
D002839:Chromans; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; C496923:KCNN4 protein, human; D026902:Potassium Channel Blockers; D024681:Potassium Channels, Calcium-Activated; D013449:Sulfonamides; C103474:6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethylchromane